Abstract
Glioblastoma (GBM) prognosis remains dismal, with most patients succumbing to disease within 1 or 2 years of diagnosis. Recent studies have suggested that many solid tumors, including GBM, are maintained by a subset of cells termed cancer stem cells (CSCs). It has been shown that these cells are inherently radio- and chemotherapy resistant, and may be maintained in vivo in a niche characterized by reduced oxygen tension (hypoxia). This review examines the recently described effects of hypoxia on CSC in GBM, and the potential promise in targeting the hypoxic pathway therapeutically.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 119-129 |
| Number of pages | 11 |
| Journal | Brain Pathology |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2011 |
Keywords
- cancer stem cells
- CD133
- digoxin
- glioma
- HIF
- hypoxia
- side population
ASJC Scopus subject areas
- Neuroscience(all)
- Pathology and Forensic Medicine
- Clinical Neurology